Clinical and Translational Gastroenterology · 2014 · 39 citations · 30 references
MedicineOncologyPharmacologyChemotherapyMolecular OncologyTumor ProgressionCancer Cell SignalingCancer ProgressionColorectal CancerMalignant NeoplasmsOncogenic Signaling PathwaysSphingolipid MetabolismMalignant ProgressionPhosphoinositide 3-Kinase PathwayPhosphoinositide 3-Kinase-akt ActivationPhosphoinositide 3-Kinase-akt SignalingPi3k-akt Signaling PathwaySphingosine 1-Phosphate SignalingSphingosine-1-phosphate SignalingTumor Cell Survival Pathways
OBJECTIVES: Sphingosine kinase 1 (SphK1) phosphorylates the membrane sphingolipid, sphingosine, to sphingosine-1-phosphate (S1P), an oncogenic mediator, which drives tumor cell growth and survival. Although SphK1 has gained increasing prominence as an oncogenic determinant in several cancers, its potential as a therapeutic target in colon cancer remains uncertain. We investigated the clinical relevance of SphK1 expression in colon cancer as well as its inhibitory effects in vitro. METHODS: SphK1 expression in human colon tumor tissues was determined by immunohistochemistry and its clinicopathological significance was ascertained in 303 colon cancer cases. The effects of SphK1 inhibition on colon cancer cell viability and the phosphoinositide 3-kinase (PI3K)/Akt cell survival pathway were investigated using a SphK1-selective inhibitor-compound 5c (5c). The cytotoxicity of a novel combination using SphK1 inhibition with the chemotherapeutic drug, 5-fluorouracil (5-FU), was also determined. RESULTS: High SphK1 expression correlated with advanced tumor stages (AJCC classification). Using a competing risk analysis model to take into account disease recurrence, we found that SphK1 is a significant independent predictor for mortality in colon cancer patients. In vitro, the inhibition of SphK1 induced cell death in colon cancer cell lines and attenuated the serum-dependent PI3K/Akt signaling. Inhibition of SphK1 also enhanced the sensitivity of colon cancer cells to 5-FU. CONCLUSION: Our findings highlight the impact of SphK1 in colon cancer progression and patient survival, and provide evidence supportive of further development in combination strategies that incorporate SphK1 inhibition with current chemotherapeutic agents to improve colon cancer outcomes.
30
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
Jacques Ferlay, Hai‐Rim Shin, Freddie Bray et al. · International Journal of Cancer · 2010 · 21.4K citations
High Frequency of Mutations of the <i>PIK3CA</i> Gene in Human Cancers
Yardena Samuels, Zhenghe Wang, Alberto Bardelli et al. · Science · 2004 · 3.4K citations
Suppression of ceramide-mediated programmed cell death by sphingosine-1-phosphate
Olivier Cuvillier, Grisha Pirianov, Burkhard Kleuser et al. · Nature · 1996 · 1.5K citations